Active Biotech – Notice of Annual General Meeting of Shareholders

The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May 15, 2014, at 5 pm at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden.
 
Please see the attached notification, which is being announced within short in Svenska Dagbladet and Post- och Inrikes Tidningar.

Lund, April 14, 2014

ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod (Nerventra®), an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod for prostate cancer and ANYARA primarily for the treatment of renal cell cancer. In addition, laquinimod Phase II clinical trials in Crohn’s and Lupus has been concluded. The company also has one additional project in clinical development, the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.

Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on April 14, 2014.

Notice of Annual General Meeting of Shareholders

—
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
HUG#1776863